Denali Therapeutics (NASDAQ:DNLI) Insider Alexander Schuth Sells 2,857 Shares

Denali Therapeutics Inc. (NASDAQ:DNLI) insider Alexander Schuth sold 2,857 shares of Denali Therapeutics stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $25.07, for a total value of $71,624.99. Following the sale, the insider owned 281,763 shares of the company’s stock, valued at approximately $7,063,798.41. This trade represents a 1.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Denali Therapeutics Trading Down 1.8%

Shares of NASDAQ DNLI traded down $0.45 during mid-day trading on Thursday, reaching $24.82. The company had a trading volume of 1,346,799 shares, compared to its average volume of 1,772,163. The stock has a market cap of $3.97 billion, a price-to-earnings ratio of -8.74 and a beta of 1.01. Denali Therapeutics Inc. has a 52 week low of $12.58 and a 52 week high of $27.30. The business’s 50-day moving average is $23.85 and its 200-day moving average is $21.43. The company has a current ratio of 8.37, a quick ratio of 8.32 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17). The company had revenue of $3.60 million for the quarter, compared to the consensus estimate of $2.15 million. During the same period last year, the firm earned ($0.72) EPS. Equities analysts expect that Denali Therapeutics Inc. will post -2.61 earnings per share for the current year.

Institutional Trading of Denali Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Denali Therapeutics in the 2nd quarter valued at $477,000. Elevation Point Wealth Partners LLC purchased a new stake in shares of Denali Therapeutics during the 2nd quarter worth $215,000. Ieq Capital LLC purchased a new stake in shares of Denali Therapeutics during the 2nd quarter worth $519,000. Allworth Financial LP bought a new stake in Denali Therapeutics during the second quarter valued at about $47,000. Finally, B. Metzler seel. Sohn & Co. AG bought a new stake in Denali Therapeutics during the second quarter valued at about $2,888,000. Institutional investors own 92.92% of the company’s stock.

Analyst Upgrades and Downgrades

DNLI has been the topic of several research reports. Robert W. Baird set a $34.00 price objective on Denali Therapeutics in a report on Friday, August 7th. BTIG Research restated a “buy” rating and issued a $39.00 price objective on shares of Denali Therapeutics in a report on Monday, May 11th. JPMorgan Chase & Co. assumed coverage on shares of Denali Therapeutics in a report on Monday, July 13th. They set an “overweight” rating and a $29.00 target price on the stock. Stifel Nicolaus set a $41.00 target price on shares of Denali Therapeutics in a research report on Monday, June 22nd. Finally, Sanford C. Bernstein restated a “hold” rating on shares of Denali Therapeutics in a report on Monday, June 22nd. Thirteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $35.92.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.